[grow_thumb image=”https://telecareaware.com/wp-content/uploads/2014/07/Baby_with_Biostamp.png” thumb_width=”180″ /][grow_thumb image=”https://telecareaware.com/wp-content/uploads/2014/07/MC10_Biostamp-small.jpg” thumb_width=”150″ /]Perhaps we should be adding to our sidebar lexicon ‘conformal electronics’.
Boston-based wearable health technology developer MC10
is partnering with Brussels-based biopharmaceutical company UCB S.A.
to develop MC10’s Biostamp platform
for treating those with severe neurological disorders. MC10 developed a seamless, disposable sensing sticker with thin film batteries (right above) which is currently in use in the Reebok Checklight
to determine sports-related concussion risk [TTA 16 May
, “Brain Games”] and in beta for infant temperature sensing (left above). It seems clear from the announcement today and further remarks (see below) that the objective is not drug delivery, but for patient monitoring and disease management. MC10 commercializes John Rogers’
work in stretchable sensor patches and batteries [TTA 10 April
]. The Biostamp does not have FDA approval but the partnership may be a way to fast-track CE approval. MC10 release, Fast Company
(also reviews Proteus, Corventis, Given Imaging
with comments from Ben Schlatka, MC10 cofounder.